| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.12▼ | 3.19▼ | 3.32▼ | 3.69▼ | 3.44▼ |
| MA10 | 3.27▼ | 3.54▼ | 3.63▼ | 3.53▼ | 5.06▼ |
| MA20 | 3.65▼ | 3.76▼ | 3.73▼ | 3.62▼ | 9.99▼ |
| MA50 | 3.62▼ | 3.51▼ | 3.52▼ | 5.44▼ | 41.97▼ |
| MA100 | 3.54▼ | 3.60▼ | 4.03▼ | 11.20▼ | 377.90▼ |
| MA200 | 3.98▼ | 5.73▼ | 6.82▼ | 24.95▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.089▼ | -0.128▼ | -0.116▼ | 0.163▲ | 4.949▲ |
| RSI | 23.108▼ | 28.674▼ | 30.925▼ | 36.506▼ | 25.014▼ |
| STOCH | 0.000▼ | 0.000▼ | 1.389▼ | 56.661 | 5.448▼ |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -95.610▼ | -96.852▼ |
| CCI | -88.138 | -124.039▼ | -148.759▼ | -106.780▼ | -87.611 |
|
Tuesday, October 13, 2026 06:51 AM
Biodexa Pharmaceuticals (NASDAQ:BDRX) has enrolled 100 patients in its registrational Phase 3 Serenta trial of eRapa for Familial Adenomatous Polyposis, with an interim futility analysis and database ...
|
|
Tuesday, September 22, 2026 08:27 AM
Biodexa Pharmaceuticals, PLC (NASDAQ: BDRX) is conducting the Phase 3 SERENTA trial of MTX230 (eRAPA) in patients with familial adenomatous polyposis (FAP). It is a double blind, placebo controlled ...
|
|
Monday, June 29, 2026 11:18 AM
On June 29, 2026, Biodexa Pharmaceuticals, PLC (NASDAQ: BDRX) announced that Health Canada gave approval for the company to expand the registrational Phase 3 SERENTA trial of MTX230 (eRapa) in ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 02/11/26 | 3.19 | 3.19 | 3.035 | 3.035 | 10,136 |
| 30/10/26 | 3.825 | 3.95 | 3.43 | 3.43 | 24,778 |
| 29/10/26 | 4.025 | 4.07 | 3.70 | 3.90 | 43,995 |
| 28/10/26 | 4.1847 | 4.23 | 3.9601 | 4.14 | 59,030 |
| 27/10/26 | 3.51 | 4.11 | 3.485 | 3.93 | 116,615 |
| 26/10/26 | 3.185 | 3.8254 | 3.185 | 3.69 | 40,189 |
| 23/10/26 | 3.08 | 3.44 | 3.08 | 3.384 | 234,400 |
| 22/10/26 | 3.20 | 3.32 | 3.128 | 3.312 | 91,200 |
| 21/10/26 | 3.192 | 3.496 | 3.064 | 3.36 | 243,500 |
| 20/10/26 | 2.992 | 3.216 | 2.976 | 3.088 | 157,400 |
|
|
||||
|
|
||||
|
|